UA74968C2 - Amlodipine bezylate tablets with improved stability and process for their preparation - Google Patents

Amlodipine bezylate tablets with improved stability and process for their preparation Download PDF

Info

Publication number: UA74968C2
Authority: UA; Ukraine
Prior art keywords: tablets; amlodipine; active ingredient; tablet; mass
Prior art date: 2001-12-17

Application number

UA20040705877A

Other languages

English (en)

Ukrainian (uk)

Original Assignee

Egyt Gyogyszervegyeszeti Gyar

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-12-17

Filing date

2002-12-17

Publication date

2006-02-15

2002-12-17 Application filed by Egyt Gyogyszervegyeszeti Gyar filed Critical Egyt Gyogyszervegyeszeti Gyar

2006-02-15 Publication of UA74968C2 publication Critical patent/UA74968C2/uk

Links

HTIQEAQVCYTUBX-UHFFFAOYSA-N amlodipine Chemical compound CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl HTIQEAQVCYTUBX-UHFFFAOYSA-N 0.000 title claims abstract description 29
238000000034 method Methods 0.000 title claims abstract description 14
229960000528 amlodipine Drugs 0.000 title abstract description 20
239000004480 active ingredient Substances 0.000 claims abstract description 33
229920000168 Microcrystalline cellulose Polymers 0.000 claims abstract description 19
239000008108 microcrystalline cellulose Substances 0.000 claims abstract description 19
235000019813 microcrystalline cellulose Nutrition 0.000 claims abstract description 19
229940016286 microcrystalline cellulose Drugs 0.000 claims abstract description 19
239000003795 chemical substances by application Substances 0.000 claims abstract description 13
239000000314 lubricant Substances 0.000 claims abstract description 10
VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims abstract description 8
229940075614 colloidal silicon dioxide Drugs 0.000 claims abstract description 6
229960004005 amlodipine besylate Drugs 0.000 claims description 31
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical compound OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 30
239000000203 mixture Substances 0.000 claims description 20
238000003825 pressing Methods 0.000 claims description 7
239000000843 powder Substances 0.000 claims description 4
239000012535 impurity Substances 0.000 description 11
238000004128 high performance liquid chromatography Methods 0.000 description 9
239000000546 pharmaceutical excipient Substances 0.000 description 9
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
238000004519 manufacturing process Methods 0.000 description 7
239000004615 ingredient Substances 0.000 description 6
238000011160 research Methods 0.000 description 6
239000011734 sodium Substances 0.000 description 5
229910052708 sodium Inorganic materials 0.000 description 5
239000000126 substance Substances 0.000 description 5
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
229920002472 Starch Polymers 0.000 description 4
230000006378 damage Effects 0.000 description 4
238000007907 direct compression Methods 0.000 description 4
239000008101 lactose Substances 0.000 description 4
235000019359 magnesium stearate Nutrition 0.000 description 4
239000000047 product Substances 0.000 description 4
239000008107 starch Substances 0.000 description 4
235000019698 starch Nutrition 0.000 description 4
229920002261 Corn starch Polymers 0.000 description 3
VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
239000008120 corn starch Substances 0.000 description 3
238000004090 dissolution Methods 0.000 description 3
238000002474 experimental method Methods 0.000 description 3
239000000945 filler Substances 0.000 description 3
IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 3
229910000041 hydrogen chloride Inorganic materials 0.000 description 3
230000014759 maintenance of location Effects 0.000 description 3
230000003647 oxidation Effects 0.000 description 3
238000007254 oxidation reaction Methods 0.000 description 3
238000003860 storage Methods 0.000 description 3
238000005550 wet granulation Methods 0.000 description 3
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 2
239000004698 Polyethylene Substances 0.000 description 2
239000011230 binding agent Substances 0.000 description 2
239000011575 calcium Substances 0.000 description 2
229910052791 calcium Inorganic materials 0.000 description 2
FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 2
238000007906 compression Methods 0.000 description 2
230000006835 compression Effects 0.000 description 2
230000032798 delamination Effects 0.000 description 2
229940079593 drug Drugs 0.000 description 2
239000012458 free base Substances 0.000 description 2
239000006187 pill Substances 0.000 description 2
-1 polyethylene Polymers 0.000 description 2
229920000573 polyethylene Polymers 0.000 description 2
230000001225 therapeutic effect Effects 0.000 description 2
LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 2
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
229930195725 Mannitol Natural products 0.000 description 1
WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000003042 antagnostic effect Effects 0.000 description 1
239000002585 base Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
235000013539 calcium stearate Nutrition 0.000 description 1
239000008116 calcium stearate Substances 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
229940105329 carboxymethylcellulose Drugs 0.000 description 1
239000000084 colloidal system Substances 0.000 description 1
238000005056 compaction Methods 0.000 description 1
229960000913 crospovidone Drugs 0.000 description 1
239000007857 degradation product Substances 0.000 description 1
235000019700 dicalcium phosphate Nutrition 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
239000003814 drug Substances 0.000 description 1
238000001035 drying Methods 0.000 description 1
230000000694 effects Effects 0.000 description 1
230000007613 environmental effect Effects 0.000 description 1
230000002349 favourable effect Effects 0.000 description 1
239000000499 gel Substances 0.000 description 1
238000005469 granulation Methods 0.000 description 1
230000003179 granulation Effects 0.000 description 1
230000005484 gravity Effects 0.000 description 1
150000002500 ions Chemical class 0.000 description 1
229940031703 low substituted hydroxypropyl cellulose Drugs 0.000 description 1
239000000594 mannitol Substances 0.000 description 1
235000010355 mannitol Nutrition 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
239000003960 organic solvent Substances 0.000 description 1
238000010525 oxidative degradation reaction Methods 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
235000013809 polyvinylpolypyrrolidone Nutrition 0.000 description 1
229920000523 polyvinylpolypyrrolidone Polymers 0.000 description 1
229910000160 potassium phosphate Inorganic materials 0.000 description 1
235000011009 potassium phosphates Nutrition 0.000 description 1
235000012239 silicon dioxide Nutrition 0.000 description 1
239000000377 silicon dioxide Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
229910001220 stainless steel Inorganic materials 0.000 description 1
239000010935 stainless steel Substances 0.000 description 1
239000007916 tablet composition Substances 0.000 description 1
238000012360 testing method Methods 0.000 description 1
238000012546 transfer Methods 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical group [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)

UA20040705877A 2001-12-17 2002-12-17 Amlodipine bezylate tablets with improved stability and process for their preparation UA74968C2 (en)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
HU0105345A HU226642B1 (en)	2001-12-17	2001-12-17	Amlodipine bezylate tablets having extended stability and process for producing the same
PCT/HU2002/000145 WO2003051364A1 (fr)	2001-12-17	2002-12-17	Comprimes d'amlopidine bezylate possedant une stabilite amelioree

Publications (1)

Publication Number	Publication Date
UA74968C2 true UA74968C2 (en)	2006-02-15

Family

ID=90000366

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
UA20040705877A UA74968C2 (en)	2001-12-17	2002-12-17	Amlodipine bezylate tablets with improved stability and process for their preparation

Country Status (17)

Country	Link
EP (1)	EP1458384B1 (fr)
AT (1)	ATE333877T1 (fr)
AU (1)	AU2002353242A1 (fr)
BG (1)	BG108807A (fr)
CZ (1)	CZ2004791A3 (fr)
DE (1)	DE60213464T2 (fr)
EA (1)	EA006826B1 (fr)
ES (1)	ES2269787T3 (fr)
HR (1)	HRP20040582B1 (fr)
HU (1)	HU226642B1 (fr)
LT (1)	LT5241B (fr)
LV (1)	LV13243B (fr)
PL (1)	PL370420A1 (fr)
RS (1)	RS54304A (fr)
SK (1)	SK2862004A3 (fr)
UA (1)	UA74968C2 (fr)
WO (1)	WO2003051364A1 (fr)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2006059217A1 (fr) *	2004-12-01	2006-06-08	Ranbaxy Laboratories Limited	Formes posologiques solides stables d'amlodipine bezylate, et procedes d'elaboration correspondants
RU2359672C1 (ru) *	2008-02-18	2009-06-27	Зао "Биоком"	Твердая лекарственная форма, предназначенная для лечения артериальной гипертензии и стенокардии, и способ ее получения
JO3239B1 (ar)	2008-09-22	2018-03-08	Novartis Ag	تركيبات جالينية من مركبات عضوية
JP4954961B2 (ja) *	2008-10-06	2012-06-20	大日本住友製薬株式会社	光安定性の向上した組成物
JP5689052B2 (ja) *	2011-12-26	2015-03-25	大日本住友製薬株式会社	光安定性の向上した組成物
US20150094345A1 (en)	2012-02-17	2015-04-02	Egis Gyogyszergyar Zrt.	Pharmaceutical formulation having improved stability
PL236001B1 (pl)	2012-12-21	2020-11-30	Adamed Spolka Z Ograniczona Odpowiedzialnoscia	Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
US10350171B2 (en)	2017-07-06	2019-07-16	Dexcel Ltd.	Celecoxib and amlodipine formulation and method of making the same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB8608335D0 (en) *	1986-04-04	1986-05-08	Pfizer Ltd	Pharmaceutically acceptable salts
DE19857716A1 (de) *	1998-12-15	2000-06-21	Bayer Ag	Neue feste Formulierung von Metrifonat
WO2003032954A1 (fr) *	2001-10-17	2003-04-24	Dr. Reddy's Laboratories Ltd.	Formulations pharmaceutiques stabilisees contenant du maleate d'amlodipine

2001
- 2001-12-17 HU HU0105345A patent/HU226642B1/hu unknown
2002
- 2002-12-17 DE DE60213464T patent/DE60213464T2/de not_active Expired - Fee Related
- 2002-12-17 EA EA200400801A patent/EA006826B1/ru not_active IP Right Cessation
- 2002-12-17 CZ CZ2004791A patent/CZ2004791A3/cs unknown
- 2002-12-17 WO PCT/HU2002/000145 patent/WO2003051364A1/fr not_active Ceased
- 2002-12-17 EP EP02788262A patent/EP1458384B1/fr not_active Expired - Lifetime
- 2002-12-17 ES ES02788262T patent/ES2269787T3/es not_active Expired - Lifetime
- 2002-12-17 SK SK286-2004A patent/SK2862004A3/sk unknown
- 2002-12-17 UA UA20040705877A patent/UA74968C2/uk unknown
- 2002-12-17 HR HR20040582A patent/HRP20040582B1/xx not_active IP Right Cessation
- 2002-12-17 RS YU54304A patent/RS54304A/sr unknown
- 2002-12-17 AU AU2002353242A patent/AU2002353242A1/en not_active Abandoned
- 2002-12-17 PL PL02370420A patent/PL370420A1/xx not_active IP Right Cessation
- 2002-12-17 AT AT02788262T patent/ATE333877T1/de not_active IP Right Cessation
2004
- 2004-07-07 LT LT2004062A patent/LT5241B/lt not_active IP Right Cessation
- 2004-07-16 LV LVP-04-82A patent/LV13243B/en unknown
- 2004-07-16 BG BG108807A patent/BG108807A/xx unknown

Also Published As

Publication number	Publication date
HRP20040582B1 (en)	2007-08-31
LT2004062A (en)	2005-02-25
HUP0105345D0 (en)	2002-02-28
EA006826B1 (ru)	2006-04-28
HRP20040582A2 (en)	2005-02-28
HUP0105345A2 (hu)	2003-12-29
BG108807A (en)	2005-03-31
AU2002353242A1 (en)	2003-06-30
CZ2004791A3 (cs)	2004-10-13
SK2862004A3 (en)	2004-11-03
EP1458384B1 (fr)	2006-07-26
ES2269787T3 (es)	2007-04-01
DE60213464D1 (de)	2006-09-07
HU226642B1 (en)	2009-05-28
EP1458384A1 (fr)	2004-09-22
WO2003051364A1 (fr)	2003-06-26
PL370420A1 (en)	2005-05-30
RS54304A (sr)	2006-12-15
EA200400801A1 (ru)	2004-12-30
LV13243B (en)	2005-05-20
ATE333877T1 (de)	2006-08-15
LT5241B (lt)	2005-07-25
DE60213464T2 (de)	2007-03-01
HUP0105345A3 (en)	2007-08-28

Publication	Publication Date	Title
Gohel et al.	2006	Preparation and assessment of novel coprocessed superdisintegrant consisting of crospovidone and sodium starch glycolate: a technical note
KR20120078751A (ko)	2012-07-10	발사르탄 및 암로디핀의 고체 투여 형태 및 이의 제조 방법
MX2012000892A (es)	2012-06-01	Formas de dosificacion de citrato ferrico.
JP2008543767A5 (fr)	2009-07-02
EP3749286A1 (fr)	2020-12-16	Composition pharmaceutique comprenant du métamizole, de la drotavérine et de la caféine
de Backere et al.	2021	Effect of binder type and lubrication method on the binder efficacy for direct compression
UA74968C2 (en)	2006-02-15	Amlodipine bezylate tablets with improved stability and process for their preparation
JP2009513530A5 (fr)	2011-01-27
US10039833B2 (en)	2018-08-07	Drug delivery system to increase bioavailability
JP7116277B2 (ja)	2022-08-10	顆粒剤、並びに錠剤及びその製造方法
WO2008020990A1 (fr)	2008-02-21	Nouveau mélange d'excipients compressible direct
GB2444904A (en)	2008-06-25	A process for the preparation of an orally administered unit dose tablet
JP2004521890A (ja)	2004-07-22	非吸湿性バルプロ酸ナトリウム組成物の製造方法
CN105456222A (zh)	2016-04-06	马来酸阿法替尼片及其制备方法
JP5644167B2 (ja)	2014-12-24	溶出改善されたケトチフェン又はその塩を含有する固形製剤
SINGH et al.	2022	Effect of ZEIN on ciprofloxacin floating tablets
EP2692342A1 (fr)	2014-02-05	Procédé pour la préparation de compositions pharmaceutiques comprenant du Febuxostat sous la forme de comprimés
Vinoth Kumar et al.	2018	Formulation and evaluation of orodispersible liquisolid compacts of nifedipine using co-processed superdisintegrants
Jadhav	2025	FORMULATION DEVELOPMENT AND EVALUATION OF NIMODIPINE AND METOPROLOL BI-LAYERED TABLETS
JP2013035826A (ja)	2013-02-21	グリメピリドを含有する口腔内崩壊錠
Mohammed et al.	2019	Effects of a co-processed novel multifunctional excipient on the tablet properties of metronidazole
Asker et al.	1981	Effect of scaling-up and formulation factors on the qualities of prednisone tablets
KR20260010448A (ko)	2026-01-20	G12c 돌연변이를 갖는 k-ras 단백질의 억제제를 포함하는 고형 제제 및 그 제조 방법
Kumar et al.	2018	Formulation and evaluation of hydralazine hydrochloride mouth dissolving tablet for the management of eclampsia and pre-eclampsia
Khalid et al.	2018	Comparative FTIR, Compaction and